LLY

914.82

+1.5%↑

JNJ

239.95

+2.09%↑

ABBV

206.56

+0.92%↑

NVS

150.73

+1.58%↑

MRK

119.31

+2.59%↑

LLY

914.82

+1.5%↑

JNJ

239.95

+2.09%↑

ABBV

206.56

+0.92%↑

NVS

150.73

+1.58%↑

MRK

119.31

+2.59%↑

LLY

914.82

+1.5%↑

JNJ

239.95

+2.09%↑

ABBV

206.56

+0.92%↑

NVS

150.73

+1.58%↑

MRK

119.31

+2.59%↑

LLY

914.82

+1.5%↑

JNJ

239.95

+2.09%↑

ABBV

206.56

+0.92%↑

NVS

150.73

+1.58%↑

MRK

119.31

+2.59%↑

LLY

914.82

+1.5%↑

JNJ

239.95

+2.09%↑

ABBV

206.56

+0.92%↑

NVS

150.73

+1.58%↑

MRK

119.31

+2.59%↑

Search

CorMedix Inc

Cerrado

SectorSanidad

6.6 2.33

Resumen

Variación precio

24h

Actual

Mínimo

6.45

Máximo

6.7

Métricas clave

By Trading Economics

Ingresos

-95M

14M

Ventas

24M

129M

P/B

Media del Sector

3.147

57.05

BPA

0.16

Margen de beneficios

10.901

Empleados

191

EBITDA

9.2M

66M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+105.11% upside

Dividendos

By Dow Jones

Próximas Ganancias

5 may 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-61M

508M

Apertura anterior

4.27

Cierre anterior

6.6

Noticias sobre sentimiento de mercado

By Acuity

35%

65%

108 / 350 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Strong Bullish Evidence

CorMedix Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

25 mar 2026, 20:20 UTC

Adquisiciones, fusiones, absorciones

Infosys Agrees to Acquire Stratus

25 mar 2026, 23:58 UTC

Ganancias

Guming Proposes 2025 Final Dividend of HK$0.50 >1364.HK

25 mar 2026, 23:58 UTC

Ganancias

Guming: Seek to Further Expand Coffee Product Line, Explore New Food Categories >1364.HK

25 mar 2026, 23:57 UTC

Ganancias

Guming: Aim to Expand Store Network in China, Evaluate Overseas Opportunities >1364.HK

25 mar 2026, 23:57 UTC

Ganancias

Guming Store Network Rose 37% on Year to 13,554 Stores as of Dec. 31, 2025 >1364.HK

25 mar 2026, 23:56 UTC

Ganancias

Guming 2025 Rev CNY12.91B Vs. CNY8.79B >1364.HK

25 mar 2026, 23:56 UTC

Ganancias

Guming 2025 Net CNY3.11B Vs. Net CNY1.48B >1364.HK

25 mar 2026, 23:41 UTC

Charlas de Mercado

Nikkei May Trade Rangebound Amid Uncertainty Over U.S.-Iran Talks -- Market Talk

25 mar 2026, 23:41 UTC

Ganancias

These Stocks Are Today's Movers: Arm, Intel, AMD, Firefly Aerospace, Robinhood, JD.com, Sarepta, and More -- Barrons.com

25 mar 2026, 23:34 UTC

Charlas de Mercado
Noticias de Eventos Importantes

Gold Declines on Possible Technical Correction -- Market Talk

25 mar 2026, 22:08 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

25 mar 2026, 22:08 UTC

Charlas de Mercado

Synlait Milk's Outlook Depends on Dunsandel -- Market Talk

25 mar 2026, 22:07 UTC

Ganancias

China Mengniu Dairy: Weak Consumer Demand Weighed on Rev >2319.HK

25 mar 2026, 22:07 UTC

Ganancias

China Mengniu Dairy Plans Steady Increase in Dividends For Next Three Years >2319.HK

25 mar 2026, 22:07 UTC

Ganancias

China Mengniu Dairy: 2025 Net Supported by Absence of Impairment Provisions Made Last Year >2319.HK

25 mar 2026, 22:07 UTC

Ganancias

China Mengniu Dairy 2025 Rev CNY82.24B Vs. CNY88.67B >2319.HK

25 mar 2026, 22:07 UTC

Ganancias

China Mengniu Dairy 2025 Net CNY1.55B Vs. Net CNY104.51M >2319.HK

25 mar 2026, 21:58 UTC

Charlas de Mercado

Amplitude Energy Oversold on Isabella-1 Well Disappointment -- Market Talk

25 mar 2026, 21:37 UTC

Charlas de Mercado

Miran: AI and Deregulation Are Positive Supply Shocks To Economy -- Market Talk

25 mar 2026, 21:14 UTC

Adquisiciones, fusiones, absorciones

St Barbara: Expects to Record Gain on Sale of Roughly A$500 Million Upon Completion

25 mar 2026, 21:13 UTC

Adquisiciones, fusiones, absorciones

St Barbara: All Conditions Satisfied, Waived on Lingbao Deal

25 mar 2026, 21:12 UTC

Adquisiciones, fusiones, absorciones

Closing M&A Deals Bring Opportunity. Janus Henderson and Other Stocks to Buy. -- Barrons.com

25 mar 2026, 20:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

25 mar 2026, 20:50 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Health Care Roundup: Market Talk

25 mar 2026, 20:33 UTC

Adquisiciones, fusiones, absorciones

KKR & Co.: Entered Agreement to Sell CoolIT Systems to Ecolab in Transaction Valued at $4.75B >KKR >KKR

25 mar 2026, 20:31 UTC

Ganancias

The SpaceX IPO Is Coming. Cathie Wood's Ark Venture and More Funds to Get in on the Action. -- Barrons.com

25 mar 2026, 20:15 UTC

Adquisiciones, fusiones, absorciones

KKR Scores One of Its Best Bets With Sale of Data-Center Cooling Business -- WSJ

25 mar 2026, 20:15 UTC

Adquisiciones, fusiones, absorciones

CoolIT Employees Set to Receive Average Payouts of $240,000, Executives Say -- WSJ

25 mar 2026, 20:15 UTC

Adquisiciones, fusiones, absorciones

CoolIT Deal Ranks Among KKR's Top-4 Highest Earning Investments in Past 20 Years, Executives Say -- WSJ

25 mar 2026, 20:15 UTC

Adquisiciones, fusiones, absorciones

KKR Set to Make 15x Investment From $4.75B Sale of CoolIT to Ecolab, Executives Say -- WSJ

Comparación entre iguales

Cambio de precio

CorMedix Inc previsión

Precio Objetivo

By TipRanks

105.11% repunte

Estimación a 12 Meses

Media 13.25 USD  105.11%

Máximo 14 USD

Mínimo 13 USD

De acuerdo con 5 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para CorMedix Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

5 ratings

5

Comprar

0

Mantener

0

Vender

Puntuación técnica

By Trading Central

9.2 / N/ASoporte y Resistencia

Corto Plazo

Strong Bullish Evidence

Medio plazo

Weak Bullish Evidence

Largo Plazo

Strong Bullish Evidence

Sentimiento

By Acuity

108 / 350 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura alcista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de CorMedix Inc

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.
help-icon Live chat